Abstract 99P
Background
Generally, cancer cell lines are established from the patients of which cancer cells are dissected, cultured and maintained in vitro. These cell lines have been traditionally used in cancer research; however, they have changed better to survive in culture condition in vitro, and not restored the original characters when they grew in vivo, meaning the lack of tumor heterogeneity. Primary culture of cancer cells derived from patients’ tumors can provide crucial information as each “individual tumor”. The primary culture method of clinical cancer and the evaluation for the treatment have not been clearly optimized in gastrointestinal cancers.
Methods
We have developed a simple 2D/3D-culture method for primary cancer. We obtained 40 clinical samples from surgically resected colorectal cancers (CRCs). They were mechanically and enzymatically digested and are filtered by customized preparation tools, followed by in vitro culture system. The gene expression profiles and the sensitivity for the drugs were analyzed.
Results
Culture cells were analyzed These cultured cancer cells were named “isolated-tumor derived Cancer Cells (iCCs).” All iCCs grew and about 90 % of iCCs were successfully passaged. These iCCs were transplanted into the subcutaneous tissue of nonobese diabetic (NOD) - severely compromised immune deficient (SCID) mice, and the tumor growth and pathological examination were evaluated. The morphology was similar to each parental clinical tumor. Microarray analyses showed that RNA expression of iCCs was similar to each parental tumor. Surface markers regarding cancer stem cells expressed in iCCs. Furthermore, multi-drug sensitivity assay by our bespoke plates including commonly used as anti-cancer/molecular target drugs was performed.
Conclusions
The iCCs are very similar to each parental tumor, leading to the personalized medicine, and the analyses of the tumor characteristics seem to reflect the clinical presentation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japanese Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract